Search Results for "Drug Interactions"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug Interactions. Results 711 to 720 of 1090 total matches.
Sapropterin (Kuvan) for Phenylketonuria
The Medical Letter on Drugs and Therapeutics • Jun 02, 2008 (Issue 1287)
of
Medicine
CONTRIBUTING EDITOR, DRUG INTERACTIONS: Philip D. Hansten,
Pharm.D.,University of Washington ...
Sapropterin (Kuvan - BioMarin) has been approved by the FDA to reduce phenylalanine plasma concentrations in patients with phenylketonuria (PKU). PKU is a rare genetic disorder (it occurs in 1 in 8000 Caucasian and 1 in 50,000 African-American newborns) caused by a deficiency of phenylalanine hydroxylase (PAH) the resulting high levels of the amino acid in blood and urine lead to cognitive, behavioral and other neurological complications.
Advertisements for TNF Inhibitors
The Medical Letter on Drugs and Therapeutics • Nov 17, 2008 (Issue 1299)
. Schwartz, M.D., Mount Sinai School of Medicine
DRUG INTERACTIONS FELLOW: Manouchkathe Cassagnol, Pharm.D ...
Some tumor necrosis factor (TNF) inhibitors are being promoted on the internet directly to the public for use in psoriasis (www.yahoo.com).
Linagliptin (Tradjenta) - A New DPP-4 Inhibitor for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • Jun 27, 2011 (Issue 1367)
Letter®
On Drugs and Therapeutics
Volume 53 (Issue 1367)
June 27, 2011
www.medicalletter.org ...
Linagliptin (Tradjenta – Boehringer Ingelheim/Lilly), a
third oral dipeptidyl peptidase-4 (DPP-4) enzyme
inhibitor, was recently approved by the FDA for treatment
of type 2 diabetes, either alone or in combination
with metformin, a sulfonylurea or pioglitazone
Eplerenone (Inspra)
The Medical Letter on Drugs and Therapeutics • May 12, 2003 (Issue 1156)
with spironolactone,
have also been reported with eplerenone.
DRUG INTERACTIONS — CYP3A4 inhibitors ...
Eplerenone (e pler' en one; Inspra - Pharmacia), an aldosterone receptor antagonist similar to spironolactone (Aldactone, and others), has been approved by the FDA, but not yet marketed, for treatment of hypertension. It has also been tried for treatment of heart failure.
Xanax XR for Panic Disorder
The Medical Letter on Drugs and Therapeutics • May 26, 2003 (Issue 1157)
The Medical Letter
On Drugs and Therapeutics
www.medicalletter.org
Published by The Medical ...
The FDA has approved an extended-release (XR) formulation of the benzodiazepine alprazolam (Xanax XR - Pfizer) for treatment of panic disorder, with or without agoraphobia. The new formulation is intended to reduce the need for frequent dosing and problems of interdose anxiety. This review describes the effectiveness of the extended-release formulation, as well as sections on dependence, abuse and withdrawal, adverse effects, and drug interactions. The review concludes with an overall assessment of the drug's efficacy and cost.
Bortezomib (Velcade) for Multiple Myeloma
The Medical Letter on Drugs and Therapeutics • Jul 21, 2003 (Issue 1161)
-drug interaction studies have been performed with bortezomib.
CLINICAL STUDIES — An open-label, non ...
Bortezomib (PS341; Velcade Millenium), the first proteasome inhibitor, has received accelerated approval from the FDA for treatment of refractory multiple myeloma. This review includes descriptions of the mechanism of action, pharmacokinetics, adverse effects, and dosage and cost of bortezomib, outlines the results of clinical studies, and concludes with an overall assessment of the drug's effectiveness.
Gefitinib (Iressa) for advanced non-small cell lung cancer
The Medical Letter on Drugs and Therapeutics • Sep 02, 2002 (Issue 1138)
commonly. Myelosuppression, renal or ocular toxicities have not occurred.
DRUG INTERACTIONS — In healthy ...
Patients with lung cancer may be asking their physicians about gefitinib (ge fi' tye nib; ZD1839; Iressa -- AstraZeneca), because it has been the subject of positive coverage in the media. An inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase, this oral drug has not been approved by the FDA, but is in clinical trials in the US for treatment of non-small cell lung cancer (NSCLC) and some other solid tumors. Iressa was recently approved in Japan, and is available from the manufacturer on a "compassionate-use" basis in the US (800-236-9933).
Low-Voltage Electronic Diagnostic Devices
The Medical Letter on Drugs and Therapeutics • Dec 01, 2008 (Issue 1300)
EDITORIAL FELLOW: Lauren K. Schwartz, M.D., Mount Sinai School of Medicine
DRUG INTERACTIONS FELLOW ...
Health care professionals may be asked about lowvoltage electronic devices now being used to diagnose and/or treat a number of health problems. Most are galvanometers that measure skin resistance to an electric current. The FDA classifies "devices that use resistance measurements to diagnose and treat various diseases" as Class III devices that require FDA approval prior to marketing. None of the devices reviewed here has such approval.
New Treatments for Metastatic Prostate Cancer
The Medical Letter on Drugs and Therapeutics • Sep 06, 2010 (Issue 1346)
hypersensitivity reactions may occur.
Drug Interactions – Strong inhibitors of CYP3A, such
as clarithromycin ...
The FDA has approved 2 new treatments for castration-resistant (formerly called hormone-refractory)
prostate cancer. Sipuleucel-T (Provenge – Dendreon) is the first immunotherapy approved for treatment of prostate cancer. Cabazitaxel (Jevtana – Sanofi-Aventis) is approved for second-line treatment of
metastatic castration-resistant prostate cancer previously treated with docetaxel (Taxotere).
Rasagiline (Azilect) for Parkinson's Disease
The Medical Letter on Drugs and Therapeutics • Dec 04, 2006 (Issue 1249)
:201.
13. The Medical Letter Adverse Drug Interactions Program.
Analgesics: meperidine (Demerol ...
Rasagiline (Azilect - Teva), a monoamine oxidase-type B (MAO-B) inhibitor, was recently approved by the FDA for once-daily oral treatment of Parkinson's disease (PD). It can be taken alone for treatment of early disease or with levodopa/carbidopa (Sinemet, and others) for advanced disease. Selegiline (Eldepryl, and others), the first MAO-B inhibitor marketed in the US, has been available since 1988; a new lower-dose disintegrating tablet (Zelapar) was recently approved.